secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0001453687-25-000050
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics receives FDA SPA agreement for Phase 3 AURORA trial of Descartes-08 in MG
--------------------------------------------------------------------------------

- FDA agrees under Special Protocol Assessment that Phase 3 AURORA trial design can support future BLA for Descartes-08 in myasthenia gravis.
- Phase 3 trial expected to start in first half of 2025; randomized, placebo-controlled, 100 AChR Ab+ participants.
- Primary endpoint: proportion with ≥3-point MG-ADL improvement at Month 4 vs placebo; 1:1 randomization.
- Phase 2b data showed average MG-ADL reduction of 5.5 (±1.1) at Month 4 (n=12); well-tolerated without preconditioning chemo.
- SPA provides regulatory clarity and a clear path toward potential approval of Descartes-08.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000050/0001453687-25-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000050/rnac-20250127.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer